Yahoo Finance

Pfizer on Tuesday reaffirmed its outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker looks to turn around its business postpandemic. The company forecast 2025 sales of between $61 billion and $64 billion and earnings per share of between $2.80 and $3, though it didn’t include any impact related to potential tariffs. Pfizer Chief Financial Officer David Denton told analysts Tuesday the company is forecasting $150 million in costs this year from the tariffs implemented to date.